(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
Thalassemia
1. Thalassemia
Dr. Kalpana Malla
MD Pediatrics
Manipal Teaching Hospital
Download more documents and slide shows on The Medical Post [ www.themedicalpost.net ]
2. AKA
• VON JAKSCH ANEMIA
• COOLEY’S ANEMIA
• “THALASSA” : GREEK WORD - GREAT SEA
– first observed - MEDITTERANIAN SEA
4. DEFINTION
• Thalassemia sydromes are a
heterogenous group of inherited anemias
characterised by reduced or absent
synthesis of either alpha or Beta globin
chains of Hb A
• Most common single gene disorder
5. BASICS - 3 types of Hb
1. Hb A - 2 α and 2 β chains forming a tetramer
• 97% adult Hb
• Postnatal life Hb A replaces Hb F by 6 months
2. Fetal Hb – 2α and 2γ chains
• 1% of adult Hb
• 70-90% at term. Falls to 25% by 1st month and
progressively
3. Hb A2 – Consists of 2 α and 2 δ chains
• 1.5 – 3.0% of adult Hb
6. INHERITANCE
• Autosomal
recessive
• Beta thal - point
mutations on
chromosome 11
• Alpha thal - gene
deletions on
chromosome 16
7. Classification
• If synthesis of α chain is suppressed – level of all
3 normal Hb A (2α ,2β),A2 (2α ,2 δ),F(2α ,2γ)
reduced – alpha thalassemia
• If β chain is suppressed - adult Hb is suppressed
- beta thalassemia
8. CLASSIFICATION
• α-thalassemia
Hb H (β4)
Hb-Bart’s ( 4)
• β-thalassemia
• β+ thal : reduced synthesis of β globin chain,
heterozygous
• β 0 thal : absent synthesis of β globin chain,
homozygous------ Hb A - absent
Hb F (α2 2)
Hb A2 (α2 δ2)
9. CLASSIFICATION OF β THALASSEMIA
CLASSIFICATION GENOTYPE CLINICAL SEVERITY
β thal minor/trait β/β+, β/β0 Silent
β thal intermedia β+ /β+, β+/β0 Moderate
β thal major β0/ β0 Severe
13. PATHOPHYSIOLOGY
• Since ẞ chain synthesis reduced -
1. gamma 2 and delta δ2 chain combines with
normally produced α chains ( Hb F (α2 2) , Hb A2
(α2 δ2) - Increased production of Hb F and Hb A2
2. Relative excess of α chains → α tetramers forms
aggregates →precipitate in red cells → inclusion
bodies → premature destruction of maturing
erythroblasts within the marrow (Ineffective
erythropoiesis) or in the periphery
(Hemolysis)→ destroyed in spleen
14. PATHOPHYSIOLOGY
Anemia result from lack of adequate Hb A
→ tissue hypoxia→↑EPO production →
↑ erythropoiesis in the marrow and
sometimes extramedullary → expansion
of medullary cavity of various bones
Liver spleen enlarge → extramedullay
hematopoiesis
15. EFFECTS OF MARROW EXPANSION
• Pathological fractures due to cortical thinning
• Deformities of skull and face
• Sinus and middle ear infection due to
ineffective drainage
• Folate deficiency
• Hypermetabolic state -> fever, wasting
• Increased absorption of iron from intestine
16. HEPATOMEGALY
• Extra medullary erythropoeisis
• Iron released from breakdown of
endogenous or transfused RBCs cannot be
utilized for Hb synthesis – hemosiderosis
• Hemochromatosis
• Infections – transfusion related - Hep B,C,
HIV
• Chronic active hepatitis
17. SPLENOMEGALY
• Extra medullary hematopoeisis
• Work hypertrophy due to constant
hemolysis
• Hypersplenism (progressive
splenomegaly)
19. INFECTIONS -CAUSES
• Poor nutrition
• Increased iron in body
• Blockage of monocyte-macrophage
system
• Hypersplenism- leukopenia
• Infections associated with transfusions
20. ACCUMULATION OF IRON
• Deposition in pituitary - endocrine
disturbance - short stature, delayed puberty,
poor sec. sexual characteristics
• Hemochromatosis - cirrhosis of liver
• Cardiomyopathy (cardiac hemosiderosis) -
cardiac failure, sterile pericarditis, arrythmias,
heart block
• Deposition in pancreas -diabetes mellitus
21. ACCUMULATION OF IRON
• Lungs: restrictive lung defects
• Adrenal insufficiency
• Hypothyroidism, hypoparathyroidism
• Increased susceptibity to infections (iron
favours bacterial growth) espc : Yersinia
infections
22. CLINICAL FEATURES (THAL MAJOR)
INFANTS:
• Age of presentation: 6-9 mo (Hb F replaced by
Hb A)
• Progressive pallor and jaundice
• Cardiac failure
• Failure to thrive, gross motor delay
• Feeding problems
• Bouts of fever and diarrhea
• Hepatosplenomegaly
23. CLINICAL FEATURES (THAL MAJOR)
BY CHILDHOOD:
Growth retardation
Severe anemia-cardiac dilatation
Transfusion dependant
Icterus
Changes in skeletal system
24. SKELETAL CHANGES
CHIPMUNK FACIES (HEMOLYTIC FACIES):
• Frontal bossing, maxillary hypertrophy, depression of nasal
bridge , Malocclusion of teeth
PARAVERTEBRAL MASSES:
• Broad expansion of ribs at vertebral attachment
• Paraparesis
PATHOLOGICAL FRACTURES:
• Cortical thinning
• Increased porosity of long bones
DELAYED PNEUMATISATION OF SINUSES
PREMATURE FUSION OF EPIPHYSES - Short stature
25. Others
• Delayed menarche
• Gall-stones, leg ulcers
• Pericarditis
• Diabetes/ cirrhosis of liver
• Evidence of hypersplenism
26. CLINICAL FEATURES (THAL
INTERMEDIA)
• Moderate pallor, usually maintains Hb >6gm%
• Anemia worsens with pregnancy and
infections (erythroid stress)
• Less transfusion dependant
• Skeletal changes present, progressive
splenomegaly
• Growth retardation
• Longer survival than Thal major
27. CLINICAL FEATURES (THAL MINOR)
• Usually ASYMPTOMATIC
• Mild pallor, no jaundice
• No growth retardation, no skeletal
abnormalities, no splenomegaly
• MAY PRESENT AS IRON DEFICIENCY ANEMIA
(Hypochromic microcytic anemia)
• Unresponsive/ refractory to Fe therapy
• Normal life expectancy
28. DIAGNOSIS - BLOOD PICTURE
• Hb – reduced (3-9mg/dl)
• RBC count – increased
• WBC, platelets – normal
• RBC indices – MCV & MCH,MCHC
reduced, RDW normal
29. BLOOD PICTURE
• PS: microcytic hypochromic anemia,
anisopoikilocytosis, target cells,
nucleated RBC, leptocytes, basophilic
stippling, tear drop cells
• Cytoplasmic incl bodies in α thal
• Post splenectomy : Howell-Jolly and
Heinz bodies
• Reticulocyte count increased (upto 10%)
30.
31. DIAGNOSIS
• Osmotic fragility test : increased- resistance
to h’lysis
• T. bilirubin, I. bilirubin – increased
• Haptoglobulin and hemopexin – depleted
• S. Fe, ferritin elevated, Transferrin –
saturated
• B.M. study: hyperplastic erythropoesis
32. DIAGNOSIS
• Red cell survival – decreased using
• Folate levels- concurrently decreased
• Free erythrocyte porphyrin - normal
• Serum uric acid-raised
• Haemosiderinuria
33. DIAGNOSIS – Hb ELECTROPHORESIS
Thal. Major - Hb F: 98 %
Hb A2: 2 %
HEMOGLOBIN
Hb A: 0 %
MAJOR MINOR NORMAL
Hb F 10-98% variable <1%
Hb A Absent 80-90% 97%
Hb A2 variable 5-10% (increased) 1-3%
34. Radiological changes
• Small bones (hand ) – earliest bony change,
rectangular appearance,medullary portion of
bone is widened &bony cortex thinned out
with coarse trabecular pattern in medulla
• Skull – widened diploid spaces – interrupted
porosity gives hair on end appearance
• Delayed pneumatization of sinuses – maxilla
appears overgrown with prominent malar
eminences
35. X ray skull:
“ hair on end”
appearance
or
“crew-cut”
appearance
36.
37. IRON OVERLOAD ASSESSMENT
• S. Ferritin
• Urinary Fe excretion
• Liver biopsy
• Chemical analysis of tissue Fe
• Endomyocardial biopsies
• Myocardial MRI indexes
• Ventricular function – ECHO, ECG
38. Treatment:
• BT at 4-6 wks interval (Hb~ 9.5 gm/dl)
Packed RBC, leucocyte-poor
• Hb to be maintained –
• Hypertransfusion : >10 gm/dl
• Supertransfusion : >12 gm/dl
• If regular transfusions- no hepatomegaly, no
facies
• 10-15ml/kg PRBC raises Hb by 3-5gm/dl –
Neocytes transfusion
• Mean cell age : 30 days
• 2-4 times more expensive
39. CHELATION THERAPY - DESFERRIOXAMINE
• ( 1 unit of blood contains 250 mg iron)
• Iron-chelating agents: desferrioxamine-
• Dose: 30-60mg/kg/day
• IV / s/c infusion pump over 12 hr period 5-6
days /wk
• Start when ferritin >1000ng/ml
• Best >5 yrs
• Vitamin C 200 mg on day of chelation -
enhances DFO induced urinary excretion of Fe
41. CHELATION THERAPY- DEFERIPRONE
• Oral chelator - > 2yrs old Dose: 50-100mg/kg/day
• Adverse effects:
Reversible arthropathy
Drug induced lupus
Agranulocytosis
• Other oral chelators
Deferrothiocine
Pyridoxine hydrazine
ICL-670 – removes Fe from myocardial cells
42. TREATMENT - SPLENECTOMY
• Deferred as long as possible. At least till 5-6
yrs age
• Splenectomy (indications):
• Massive splenomegaly causing
mechanical discomfort
• Progressively increasing blood
transfusion requirements (>180-200
ml/kg/yr) packed RBC
43. BONE MARROW TRANSPLANTATION
• BEST METHOD FOR CURE
• Risk factors:
Hepatomegaly >2cm
Portal fibrosis
Iron overload
Older age
44. Newer therapies:
• GENE MANIPULATION AND REPLACEMENT
• Remove defective β gene and stimulate γ gene
• 5-azacytidine increases γ gene synthesis
• Hb F AUGEMENTATION
• Hydroxyurea
• Myelaran
• Butyrate derivatives
• Erythropoetin in Thal intermedia
45. OTHER SUPPORTIVE MEASURES
• Tea – thebaine and tannins– chelate iron
• Vitamin C – increases iron excretion
• Restrict Fe intake – decrease meat, liver, spinach
• Folate – 1 mg/day
• Genetic counselling
• Psychological support
• Hormonal therapy – GH, estrogen, testosterone,
L-thyroxine
• Treatment of CCF
51. α-thalassemia:
• Deletion on alpha globin locus on Chr 16
• Defective synthesis of α-globin chain
• Excess of - chains - in the fetus (Hb Bart- 4)
Excess of β-chains in the adult (Hb H- β4)
53. ALPHA THALASSEMIA
• Highest prevalence in Thailand
• α chains shared by fetal as well as adult life.
Hence manifests both times
• These thalassemias don’t have ineffective
erythropoesis because β and γ are soluble chains
and hence not destroyed always
• α Thalassemia trait mimics Fe deficiency anemia
• Silent carrier – silent – not identified
hematologically, diagnosed when progeny has Hb
Barts/ Hb H
55. Hb H DISEASE
• Seen in SEA, middle east
• Moderate anemia (Hb 8-9 gm/dl), mild jaundice
• Splenomegaly, gall stones
• PBS similar to thal major
• Hb electrophoresis: Hb H 2-40 %; rest are Hb A,
HbA2, HbF
• Not very transfusion dependant
• Bony deformities
56. Hb BARTS
• Hb Barts has γ4, then later in infancy β4
• Severe hypoxia as Hb Barts has high affinity for
oxygen
57. Haemoglobin Bart’s:
• Most severe manifestation of alpha thalassemia
• Hydrops fetalis – Fatal unless intrauterine transfusions
• Stillborn or die within a few hours
• Severe anemia , edematous, mildly jaundiced,
ascites, hepatosplenomegaly, cardiac failure
• Looks like Rh incompatilibity
• Increased incidence of toxemia
of pregnancy
58. • DIAGNOSIS
• Hb electrophoresis:
80-90 % Hb Bart’s
Hb H
Hb Portland
No Hb A, Hb A2 or Hb F
• Treatment: immediate exchange transfusion
59. DIAGNOSIS OF α THALASSEMIA
• CBC, PS, BM study
• Heinz bodies in HbH disease – brilliant cresyl
blue
• Hb electrophoresis – for HbH and Hb Barts
• α/β chain ratio decreased
60. Treatment:
• Generally not reqd
• Blood transfusion , iron chelation therapy –
For transfusion dependent cases
• Avoidance of oxidant drugs
• Prompt treatment of infections
• Folic acid supplementation
• Splenectomy
• BM transplantation, gene therapy
61. Thank you
Download more documents and slide shows on The
Medical Post [ www.themedicalpost.net ]